Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07527559

Fuzzle System for Appetite Control and Weight Management

This study is evaluating whether the Fuzzle intraoral device can help adults with obesity lose weight when used alongside standard lifestyle counseling.

Participants in this study will receive guidance on diet and behavior to support weight loss. Some participants will also receive the Fuzzle device, a custom-made removable oral appliance worn during the day.

The study will compare weight loss outcomes between participants who use the Fuzzle device and those who follow lifestyle counseling alone over a 16-week period.

Researchers will also explore whether use of the device increases the number of participants who achieve meaningful weight loss and may evaluate changes in selected metabolic markers in a subset of participants.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Obesity & Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

DM Clinical Research

Bradenton, Florida, 34209, United States

About this study

The purpose of this study is to evaluate the effectiveness of the Fuzzle intraoral device as an adjunct to standardized lifestyle counseling for weight management in adults with obesity (BMI ≥30 kg/m², ages 18-65).

This randomized, controlled study compares participants receiving the Fuzzle device in combination with standardized lifestyle counseling to those receiving lifestyle counseling alone over a 16-week period.

The primary objective is to assess whether use of the Fuzzle device results in greater percent total body weight loss at 16 weeks compared to standardized lifestyle counseling alone.

All participants receive standardized dietary and behavioral counseling, including caloric targets based on estimated energy expenditure and structured adherence support with regular follow-up. This design is intended to isolate the effect of the device as an adjunctive intervention to a controlled behavioral baseline.

The Fuzzle intraoral device is a custom-fabricated, removable oral appliance designed for daytime wear. It is intended to modulate oral sensory input within the stomatognathic system to influence eating-related behaviors, including reductions in snacking frequency and alterations in meal patterns. The device is non-invasive, reversible, and used in a home setting under provider supervision.

A subset of participants will provide blood samples for exploratory metabolic markers, including HbA1c, hsCRP, and ALT.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-65 years
  • Body mass index (BMI) ≥30 kg/m² at screening
  • Willing and able to provide informed consent
  • Willing to comply with study visits and procedures
  • Willing to participate in standardized lifestyle counseling

Exclusion criteria

  • Participation in another weight-loss clinical study within 90 days
  • Pregnancy, breastfeeding, or intent to become pregnant during the study period
  • History of eating disorders or uncontrolled psychiatric illness
  • Oral or dental conditions preventing safe device use
  • Current use of prescription or over-the-counter weight-loss medications
  • A1C >8.0% at screening (glycemic subset exclusion only)
  • Unstable diabetes medication regimen (glycemic subset exclusion only)
  • Any medical condition that, in the investigator's judgment, would interfere with safe participation

Treatment and study plan

Fuzzle Intraoral Device

Device

The Fuzzle intraoral device is a custom-fabricated, removable oral appliance designed for daytime wear as an adjunct to weight management. The device is created from dental impressions to ensure a patient-specific fit. Participants are instructed to wear the device during waking hours, excluding meals and oral hygiene.

The device is intended to modulate oral sensory input within the stomatognathic system, with the goal of influencing eating-related behaviors, including reductions in snacking frequency and alterations in meal patterns. It is non-invasive, reversible, and used in a home setting under provider supervision.

Other names: Fuzzle, Fuzzle Device

Lifestyle Management

Behavioral

Participants receive standardized lifestyle management including dietary guidance, caloric targets based on estimated energy expenditure, and structured behavioral counseling. Participants track food intake using a mobile application with weekly check-ins to reinforce adherence.

Primary outcomes

  1. Percent Total Body Weight Loss (%TBWL) at 16 Weeks

    Time frame: From study enrollment to completion at 16 weeks

    Percent total body weight loss (%TBWL) will be compared between study arms at Week 16. %TBWL is calculated as [(baseline body weight - Week 16 body weight) ÷ baseline body weight] × 100, where higher values indicate greater weight loss. Body weight will be measured using standardized procedures during in-person clinic visits.

Secondary outcomes

  1. Change in Body Mass Index (BMI)

    Time frame: From study enrollment to completion at 16 weeks

    Body mass index (BMI, kg/m²) will be calculated as weight in kilograms divided by height in meters squared and compared between study arms based on change from baseline to Week 16.

  2. Proportion of Participants Achieving ≥5% Total Body Weight Loss

    Time frame: Baseline to Week 16

    The proportion of participants achieving at least 5% reduction from baseline body weight at Week 16 will be compared between study arms.

  3. Change in Waist Circumference

    Time frame: Baseline to Week 16

    Waist circumference (cm) will be measured using standardized methods at clinic visits and compared between study arms based on change from baseline to Week 16.

  4. Change in Weight-Related Quality of Life (IWQOL-Lite-CT)

    Time frame: Baseline to Week 16

    Weight-related quality of life will be assessed using the IWQOL-Lite-CT instrument, with scores compared between study arms based on change from baseline to Week 16. Higher scores indicate improved quality of life.

  5. Device Tolerability Assessed by Oral Comfort Visual Analog Scale (VAS), Adverse Event Incidence, and Device Adherence Metrics

    Time frame: Baseline to Week 16

    Fuzzle system tolerability will be evaluated using participant-reported comfort, safety monitoring, and adherence to use. Oral comfort will be assessed using a 10-point Visual Analog Scale (VAS), where 0 indicates no discomfort and 10 indicates extreme discomfort, collected at regular intervals throughout the study period. Adverse events will be recorded and categorized by frequency, severity (mild, moderate, severe), and relationship to the Fuzzle system. Device adherence will be measured using system-recorded and/or participant-reported usage, including average daily wear time and percentage of prescribed use over the study period.

  6. Exploratory Change in High-Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline to Week 16

    In a predefined subset of participants with baseline HbA1c between 5.7% and 7.5%, change from baseline to Week 16 in high-sensitivity C-reactive protein (hsCRP), measured in milligrams per liter (mg/L), will be evaluated. Analyses will be descriptive.

  7. Exploratory Change in Alanine Aminotransferase (ALT)

    Time frame: Baseline to Week 16

    In a predefined subset of participants with baseline HbA1c between 5.7% and 7.5%, change from baseline to Week 16 in alanine aminotransferase (ALT), measured in units per liter (U/L), will be evaluated. Analyses will be descriptive.

Other outcomes

  1. Exploratory Change in Glycated Hemoglobin (HbA1c)

    Time frame: From study enrollment to completion at 16 weeks

    In a predefined subset of participants with baseline HbA1c between 5.7% and 7.5%, change from baseline to Week 16 in glycated hemoglobin (HbA1c), measured as a percentage (%), will be evaluated. Analyses will be descriptive.

Study contacts

Contact information is provided by the study sponsor or research team.

Brandon Essink, MD

CONTACT

[email protected]

941-667-2796

Jeremy McConnell, MD

CONTACT

[email protected]

941-667-2796

Sponsors and collaborators

Lead sponsor

Fuzzle Operating Co.

Industry

Collaborators

  • Advarra
  • Dynamed Clinical Research

Registry information

Official study title

A Randomized Controlled Study Evaluating the Safety and Effectiveness of the Fuzzle Intraoral Device for Weight Management

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 14, 2026
Registry last updated
Apr 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.